Compare Abeona Therapeutics Inc (ABEO) vs Iron Mountain Inc (IRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Iron Mountain Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Iron Mountain Inc trades at $122.75 (market cap $36.19B). The key difference: Iron Mountain Inc is far larger — about 85.3× Abeona Therapeutics Inc's market cap, and Iron Mountain Inc pays a 2.84% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | IRM | |
|---|---|---|
Market Cap | $424.33M | $36.19B |
Sector | Health | Real Estate |
52-Week High | $7.45 | $133.06 |
52-Week Low | $4.17 | $78.86 |
Enterprise Value | $279.23M | $55.60B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Iron Mountain (IRM) trades at $121.15, down 0.66% on the day, amid a bearish technical signal. The company reported strong Q2 2026 results with revenue up 19% year-over-year to $2.03 billion, beating estimates, and has a consensus analyst price target of $141.50. However, high debt levels and a negative shareholder equity position present fundamental concerns.
Outlook is mixed: robust data center and digital growth support upside, but elevated valuation ratios and rising debt-to-asset ratios pose risks. Analyst sentiment is predominantly buy-rated (65%), yet technical indicators suggest near-term caution. Investors should weigh strong operational performance against financial leverage and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →
